UCLA Scleroderma Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Best Pract Res Clin Rheumatol. 2010 Jun;24(3):387-400. doi: 10.1016/j.berh.2009.12.002.
Systemic sclerosis has the highest case-specific mortality of any of the auto-immune rheumatic diseases, as well as causing major morbidity. It is a major clinical challenge and one that has previously provoked substantial nihilism due to the limited therapeutic options available and the perceived lack of evidence for clinical effectiveness of those treatments that are currently in use. However, this situation is changing; there are emerging data supporting efficacy for some treatment approaches for this patient group together with a growing number of exciting potential novel approaches to treatment that are moving into the clinical arena. Some of the recent clinical trials are reviewed and discussed in detail.
系统性硬化症是自身免疫性风湿病中病死率最高的疾病，同时也导致了严重的发病率。这是一个重大的临床挑战，由于可用的治疗选择有限，以及目前使用的治疗方法缺乏临床疗效的证据，此前曾引起了相当大的虚无主义。然而，这种情况正在发生变化；有越来越多的数据支持一些治疗方法对这一患者群体的有效性，同时也有越来越多令人兴奋的潜在新的治疗方法正在进入临床领域。本文详细回顾和讨论了一些最近的临床试验。
